Nasdaq
$13.47▲ 2.36%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.39BShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 2d agoPre-market26.10.23 21:008-KKey event#●●●#●●●#●●●
Oric Pharmaceuticals, Inc.Bullish
Oric Pharmaceuticals presented Phase 1b data for enozertinib (ORIC-114) at ESMO 2026, demonstrating an 84% objective response rate (ORR) in the first-line setting. Based on these results and discussions with the FDA, the company plans to initiate the global Phase 3 'Redwood-1' trial in the first half of 2027, targeting approximately 360 patients with EGFR atypical NSCLC.…more
$13.47+2.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 06:174Ownership
Oric Pharmaceuticals, Inc.
Insider Dominic Piscitelli of Oric Pharmaceuticals reported a change in beneficial ownership of securities as of October 20, 2026. This filing serves as a standard disclosure of executive equity transactions and does not contain any material financial or operational updates.…more
$13.47+2.36%vs prev closeView filingShare - 10.2After-hours26.10.03 06:504Ownership
Oric Pharmaceuticals, Inc.
Director Richard A. Heyman of Oric Pharmaceuticals, Inc. filed a Form 4 report regarding a change in beneficial ownership of company securities effective October 1, 2026. This filing serves as an official disclosure of insider transaction activity.…more
$13.47+2.36%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoOvernight26.10.23 16:15#●●●#●●●#●●●
ORIC Pharmaceuticals Reports Positive Enozertinib Data and Plans Global Phase 3 Trial…more
ORIC Pharmaceuticals presented promising Phase 1b data for its EGFR-mutant NSCLC treatment, enozertinib, at the ESMO Congress. The company plans to initiate a global Phase 3 registrational trial in the first half of 2027.…more
$13.47+2.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5After-hours26.10.06 05:01
●●●●●●●● ●●●●● ●●●●●●
ORIC Pharmaceuticals has partnered with Cancer Research UK to advance its CIP2A-targeted therapy, ORIC-259, into clinical development. Under the agreement, CRUK will fully fund and manage the early-stage clinical trials, while ORIC retains an option to reacquire the rights later.…more
$13.47+2.36%vs prev close - 10.2After-hours26.10.03 05:30
●●●●●●●● ●●●●● ●●●●●●
ORIC Pharmaceuticals has granted stock options and restricted stock units to six new employees as an inducement for their employment. This is a standard equity incentive grant under Nasdaq rules and does not represent a material change in company performance.…more
$13.47+2.36%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report